Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 4, 2003. The report primarily details changes in directors' interests in the company's Ordinary Shares and American Depository Shares (ADSs) for the service period of January 1, 2003, to March 31, 2003.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director share allocations rather than consolidated financial performance.
Material Changes and Transactions
- Director Share Allocations: On April 1, 2003, non-executive directors received provisional awards under automatic share allocation and share election arrangements for the first quarter of 2003.
- Trust Transactions: The GlaxoSmithKline Employee Trust (GSK Trust) sold 1,156 Ordinary Shares at £11.2700 per share and transferred 1,683 Ordinary Shares on behalf of participants in the Glaxo Wellcome 1999 Long Term Incentive Plan.
- Director Interests: Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in shares held within the GSK Trust as potential beneficiaries.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risk factors, contingencies, or unusual items. The content is limited to regulatory disclosure of share ownership changes.
Key Facts for Investor Verification
- Verify the total number of Ordinary Shares and ADSs allocated to non-executive directors for Q1 2003.
- Confirm the transaction price of £11.2700 per share for the GSK Trust sale on April 1, 2003.
- Review the specific share counts for individual directors listed in the automatic and election allocation tables.
- Understand that this filing does not contain financial performance data for the period.